SAN DIEGO, July 7 /PRNewswire-FirstCall/ -- SpectraScience, Inc. , a San Diego based medical device company, today announced that it has established a distribution partnership in France through Medipartner, a Paris based firm specializing in the marketing and distribution of innovative gastrointestinal medical devices. The Company believes that building an effective distribution network in France will also enhance sales in the emerging North African and Middle Eastern markets due to their relationship with France.
Michel Vaudry, SpectraScience’s VP of Sales and Marketing, said, “We are pleased to add Medipartner to our expanding distribution footprint throughout Europe, and are optimistic that physicians and more importantly, patients in France will greatly benefit from the introduction of WavSTAT to this market. In terms of cancers plaguing France’s population, colon cancer has one of the highest rates of incidence and mortality.”
Medipartner’s Chief Executive, Christian Arnould, stated that, “We decided to add the WavSTAT to products that we distribute because it is both innovative and it will translate into progress for cancer detection. Our focus is in the gastrointestinal market, and based on our experience and understanding of that market, I think that the WavSTAT is a great fit for us, and our customers.” Medipartner is the French distributor for Sandhill Scientific, a leading international GI diagnostics company based in Colorado.
“We are shipping a unit to France this week,” added Vaudry. “I will be going to France to assist Christian in making demonstrations of the WavSTAT to physicians at several healthcare centers of excellence, including the Hospital Edourard Herriot in Lyon, which has just been ranked as one of the 10 best healthcare centers in the world by Newsweek magazine.” In addition, Mr. Vaudry noted that Lyon is the headquarters of the International Agency for Research on Cancer (IARC), one of the most prestigious cancer research facilities in operation today.
Forward-Looking Statements
This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements involve risks and uncertainties that may cause SpectraScience’s actual results to differ materially from results discussed in forward-looking statements. Readers are urged to carefully review and consider the various disclosures made by SpectraScience in this news release, its most recent Form 10-K and in SpectraScience’s other reports filed with the Securities and Exchange Commission (“SEC”) that attempt to advise interested parties of the risks and factors that may affect SpectraScience’s business. These forward-looking statements are qualified in their entirety by the cautions and risk factors filed by SpectraScience in its annual report on Form 10-K and other documents.
About SpectraScience, Inc.
SpectraScience is a San Diego based medical device company that designs, develops, manufactures and markets spectrophotometry systems capable of determining whether tissue is normal, pre-cancerous or cancerous without physically removing tissue from the body. The WavSTAT Optical Biopsy System uses light to optically scan tissue and provides the physician with an immediate analysis. With FDA approval for sale in the U.S. and the CE Mark for the European Union, the WavSTAT System is the first commercially available product that incorporates this innovative technology for clinical use. In addition, the Company’s LUMA(R) Cervical Imaging technology has received FDA approval as an optical non-invasive system that is proven to more effectively detect cervical cancer precursors than conventional methods available today.
CONTACT: Communications, Jim Hitchin, Chief Executive Officer,
SpectraScience, Inc., +1-858-847-0200, ext. 201; Investor Relations, Todd
Pitcher, Hayden, +1-858-518-1387
Web site: http://www.spectrascience.com/
